Your browser doesn't support javascript.
loading
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
de la Cruz-Merino, L; Gion, M; Cruz, J; Alonso-Romero, J L; Quiroga, V; Moreno, F; Andrés, R; Santisteban, M; Ramos, M; Holgado, E; Cortés, J; López-Miranda, E; Cortés, A; Henao, F; Palazón-Carrión, N; Rodriguez, L M; Ceballos, I; Soto, A; Puertes, A; Casas, M; Benito, S; Chiesa, M; Bezares, S; Caballero, R; Jiménez-Cortegana, C; Sánchez-Margalet, V; Rojo, F.
Afiliação
  • de la Cruz-Merino L; Department of Medical Oncology, Medicine Department, Virgen Macarena University Hospital, University of Seville, Dr. Fedriani St, No. 3, Seville, 41009, Spain. luis.cruz.sspa@juntadeandalucia.es.
  • Gion M; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain. luis.cruz.sspa@juntadeandalucia.es.
  • Cruz J; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Alonso-Romero JL; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Quiroga V; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Moreno F; Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • Andrés R; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Santisteban M; Department of Medical Oncology, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, Murcia, Spain.
  • Ramos M; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Holgado E; Department of Medical Oncology, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain.
  • Cortés J; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • López-Miranda E; Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain.
  • Cortés A; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Henao F; Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain.
  • Palazón-Carrión N; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Rodriguez LM; Department of Medical Oncology, Clínica Universidad de Navarra, Navarra, Spain.
  • Ceballos I; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Soto A; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Puertes A; Department of Medical Oncology, Centro Oncológico de Galicia, A Coruña, Spain.
  • Casas M; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Benito S; Department of Medical Oncology, Hospital La Luz, Quironsalud, Madrid, Spain.
  • Chiesa M; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Bezares S; International Breast Cancer Center (IBCC), Quiron Group, Barcelona and Madrid, Spain.
  • Caballero R; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Jiménez-Cortegana C; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.
  • Sánchez-Margalet V; GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, Spain.
  • Rojo F; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
BMC Cancer ; 22(1): 1258, 2022 Dec 03.
Article em En | MEDLINE | ID: mdl-36463104

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Ano de publicação: 2022 Tipo de documento: Article